Schwab Charles Investment Management Inc. increased its stake in Omeros Co. (NASDAQ:OMER) by 10.2% in the third quarter, Holdings Channel reports. The institutional investor owned 217,804 shares of the biopharmaceutical company’s stock after acquiring an additional 20,139 shares during the quarter. Schwab Charles Investment Management Inc.’s holdings in Omeros were worth $4,709,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of OMER. Russell Investments Group Ltd. increased its stake in shares of Omeros by 87.4% in the second quarter. Russell Investments Group Ltd. now owns 36,160 shares of the biopharmaceutical company’s stock worth $720,000 after buying an additional 16,862 shares during the last quarter. Rhumbline Advisers boosted its holdings in Omeros by 1.8% in the second quarter. Rhumbline Advisers now owns 46,632 shares of the biopharmaceutical company’s stock worth $928,000 after purchasing an additional 832 shares during the period. State of Wisconsin Investment Board acquired a new position in Omeros in the second quarter worth $458,000. Bank of New York Mellon Corp boosted its holdings in Omeros by 1.9% in the second quarter. Bank of New York Mellon Corp now owns 229,959 shares of the biopharmaceutical company’s stock worth $4,577,000 after purchasing an additional 4,376 shares during the period. Finally, Legal & General Group Plc boosted its holdings in Omeros by 7.8% in the second quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 751 shares during the period. Institutional investors and hedge funds own 49.71% of the company’s stock.

A number of equities analysts have commented on the stock. Maxim Group set a $24.00 price objective on shares of Omeros and gave the stock a “buy” rating in a report on Tuesday, December 12th. HC Wainwright set a $30.00 price objective on shares of Omeros and gave the stock a “buy” rating in a report on Wednesday, November 29th. Cowen downgraded shares of Omeros from an “outperform” rating to a “market perform” rating in a report on Thursday, November 2nd. Finally, Zacks Investment Research downgraded shares of Omeros from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Five investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $34.14.

Omeros Co. (NASDAQ:OMER) opened at $19.84 on Thursday. The company has a market cap of $952.39, a price-to-earnings ratio of -15.38 and a beta of 3.56. The company has a quick ratio of 4.74, a current ratio of 4.77 and a debt-to-equity ratio of 8.99. Omeros Co. has a 1-year low of $8.71 and a 1-year high of $27.09.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.18. The business had revenue of $21.66 million during the quarter, compared to analyst estimates of $17.82 million. During the same period in the prior year, the firm earned ($0.34) EPS. The business’s revenue for the quarter was up 91.9% compared to the same quarter last year. equities analysts forecast that Omeros Co. will post -0.98 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://theolympiareport.com/2018/01/11/omeros-co-omer-shares-bought-by-schwab-charles-investment-management-inc.html.

About Omeros

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Co. (NASDAQ:OMER).

Institutional Ownership by Quarter for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.